# EDGAR Filing Document

**Accession Number:** 0001379006
**File Stem:** 0001104659-23-019813
**Filing Date:** 2023-2
**Character Count:** 5213
**Document Hash:** ea5cf12f39611ede5d46d7a1375a9c04
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-019813.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0001104659-23-019813

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230207

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NANOVIRICIDES, INC.
- **CENTRAL INDEX KEY:** 0001379006
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 760674577
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36081
- **FILM NUMBER:** 23619591

**BUSINESS ADDRESS:**
- **STREET 1:** 1 CONTROLS DRIVE
- **CITY:** SHELTON
- **STATE:** CT
- **ZIP:** 06484
- **BUSINESS PHONE:** (203) 937-6137

**MAIL ADDRESS:**
- **STREET 1:** 1 CONTROLS DRIVE
- **CITY:** SHELTON
- **STATE:** CT
- **ZIP:** 06484

?xml version="1.0" encoding="utf-8"?

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

---

| | |
|:---|:---|
| Date of report (Date of earliest event reported) | &nbsp;&nbsp;**February 7, 2023** |

---

---

| |
|:---|
| **NANOVIRICIDES, INC.** |
| (Exact Name of Registrant as Specified in Its Charter) |

---

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-36081** | **76-0674577** |
| (State or Other Jurisdiction of<br> Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| **1 Controls Drive,<br> Shelton, Connecticut** | **1 Controls Drive,<br> Shelton, Connecticut** | **06484** |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Zip Code) |

---

---

| |
|:---|
| **(203) 937-6137** |
| (Registrant's Telephone Number, Including Area Code) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class:** | **Trading Symbol(s)** | **Name of each exchange on which registered:** |
| Common Stock | NNVC | NYSE-American |

---

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On February 7, 2023, NanoViricides, Inc. (the "Company") reconvened its 2022 Annual Meeting of Stockholders (the "Meeting"). Of the 11,610,037 shares of the Company's common stock and 495,173 shares of Series A Convertible Preferred Stock ("Series A Preferred Shares") entitled to vote at the Meeting, an aggregate of 56% of the Registrant's securities entitled to vote were present in person or by proxy, representing a majority of the Company's outstanding voting capital stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At the Meeting, shareholders of the Company approved the redomicile of the Company from a Nevada corporation to a Delaware corporation. The proposal is described in more detail in the Company's Proxy Statement filed with the Securities and Exchange Commission on November 15, 2022.

The voting results of the shares of the Company's voting stock for the proposal is set forth below:

**Proposal 1** – The Redomicile of the Company as a Delaware Corporation:

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Votes For** | **Votes Against/Withheld** |
| 8,115,210 | 942,379 |

---

**SIGNATURES**

**PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.**

---

| | | |
|:---|:---|:---|
|  | **NANOVIRICIDES, INC.** | **NANOVIRICIDES, INC.** |
| Date: February 13, 2023. | By: | */s/ Anil Diwan* |
|  |  | Name: Anil Diwan |
|  |  | Title: Chairman, President |

---